Affecting an estimated 35% of the population, musculoskeletal conditions and injuries are among the leading contributors of disability worldwide as they significantly limit mobility and dexterity. Caused by damage to the tissues of the musculoskeletal system due to overuse, physiological aging processes and injury, they result in the disorganisation and loss of the integrity of the collagen fibres that provide mechanical support to the whole body, leading to impaired mobility and functionality, and pain. Collagen deficiency is also always present in osteo-arthro-myofascial pathologies.

Collagen therapy is therefore vital in slowing down degenerative processes and repairing the damaged tissues of the musculoskeletal system.

Guna Collagen Medical Devices

Now available in South Africa, Guna Collagen Medical Devices have been developed to manage the processes of repair and remodelling of damaged musculoskeletal tissue to ensure functional recovery.

Administered by intra-articular, peri-articular, intra-muscular, intra-dermal injections, Guna Collagen Medical Devices comprise of 13 different injectable class 3 devices that have been developed to treat painful conditions affecting the musculoskeletal system. Containing collagen and specific ancillary substances of natural origin, the different products are aimed at treating specific skeletal areas where the damage or injury has occurred as well as diseases that affect the tissues of mesodermal origin such as rheumatoid- and osteoarthritis.

The objectives of the treatments are to replace, strengthen, protect and build the histological structure of the collagen fibres, limit the physiological degeneration of joints and tissues and relieve pain.

Use of Guna Collagen Medical Devices

The devices can be used for three types of clinical cases in orthopaedics-traumatology:

• overuse pathologies;

• the aging processes that affect the tissues derived from the mesoderm, such as bones, tendons, ligaments, muscles and, in general, in the ailments of the extra-cellular matrix;

• degenerative phenomena secondary to chronic inflammatory processes of traumatic origin.

 Although the devices are effective in relieving acute and chronic benign pain affecting the musculoskeletal system, they cannot and should not be considered painkillers. The pain relief experienced is only a secondary action due to the stabilisation of the joint, resulting in decreased stimulation of the nociceptive endings. Each protocol must be adapted to the patient’s medical history and the specific clinical case.

Different treatments for different areas

Apart from collagen, each of the 13 Guna Collagen Medical Device contain different auxiliary substances aimed at treating specific areas based on the substance’s tropism for one or more specific tissues. This is in accordance with herbal medicine pharmacokinetics (for plant-derived auxiliary substances) or with metabolic mechanisms (for mineral substances, vitamins and trace elements). Each auxiliary substance has been chosen to optimise the effect of the collagen and to obtain the best tropism toward the targeted area.


The collagen contained in Guna Collagen Medical Devices is type I collagen of porcine origin which is similar to human collagen, guaranteeing a high level of safety due to its very low immunogenicity.

To obtain a safe product without contaminants, with standardised chemical-physical characteristics, the collagen of Guna Collagen Medical Devices undergoes three manufacturing processes:

• identification and conformity check of the porcine tissue

• extraction phase

• preparation and sterilisation/ viral inactivation of the collagen extract.

No side effects, allergic reactions nor drug interactions have been observed except for a slight reddening in the injection area due to the mechanical action of the needle.

Treatment and management

In the acute phase of the disease daily treatment for three consecutive days is recommended followed with two treatments weekly until complete remission of symptoms and then one treatment weekly for six consecutive weeks. One treatment may be useful three month after the last session of treatment followed by one treatment every three months.


A virtual CPD accredited webinar on Clinical Innovations in the Treatment of Joint, Musculoskeletal and Myofascial Conditions will be held on 20 October at 19h00.

For more information and to register, go to: